AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17593233 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) with a short‐acting insulin analogue, 2 IU/h, for 8 h during three consecutive nights (period A)
Number of subjects: 10
Study 17593233 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) with a short‐acting insulin analogue, 2 IU/h, for 8 h during three consecutive nights (period B and C)
Number of subjects: 10
Study 15886752 — intervention group
Group type: COMPARATOR
Intervention: Estradiol in Group A (AD)
Number of subjects: 88
Study 15886752 — intervention group
Group type: COMPARATOR
Intervention: Progesterone in Group A (AD)
Number of subjects: 88
Study 15886752 — intervention group
Group type: COMPARATOR
Intervention: Testosterone in Group A (AD)
Number of subjects: 88
Study 15886752 — intervention group
Group type: COMPARATOR
Intervention: FSH in Group A (AD)
Number of subjects: 88
Study 15886752 — intervention group
Group type: COMPARATOR
Intervention: LH in Group A (AD)
Number of subjects: 88
Study 12519875 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of GH treatment (3 IU/m2 x d)
Number of subjects: 47
Study 12519875 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of GH treatment (6 IU/m2 x d)
Number of subjects: 47
Study 12519875 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 47
Study 12519875 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of GH treatment (both dosage groups)
Number of subjects: 47
Study 11191785 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level (procedure-based) training
Number of subjects: 25
Study 11191785 — intervention group
Group type: EXPERIMENTAL
Intervention: High level (system-based) training
Number of subjects: 25
Study 11191785 — intervention group
Group type: EXPERIMENTAL
Intervention: First testing session
Number of subjects: 25
Study 11191785 — intervention group
Group type: EXPERIMENTAL
Intervention: Second testing session (8 months later)
Number of subjects: 25
Study 9169959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone 200 mg daily for 1 week, followed by 400 mg daily for 7 weeks
Number of subjects: 43
Study 9169959 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg daily
Number of subjects: 43
Study 1328700 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR
Number of subjects: 77
Study 1328700 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral culture
Number of subjects: 77
Study 1328700 — intervention group
Group type: EXPERIMENTAL
Intervention: Tzanck smear
Number of subjects: 77
Study 1328700 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 2866047 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg/day)
Number of subjects: 19
Study 2866047 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (150 mg/day)
Number of subjects: 19
Study 2866047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30184183 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV10
Number of subjects: 262
Study 30184183 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 262
Study 30184183 — intervention group
Group type: COMPARATOR
Intervention: PCV10 and PCV13
Number of subjects: 262
Study 29769133 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) 1
Number of subjects: 0
Study 29769133 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) 2
Number of subjects: 0
Study 29769133 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 0
Study 27428209 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐Asc plus simethicone
Number of subjects: 260
Study 27428209 — intervention group
Group type: COMPARATOR
Intervention: PEG‐Asc
Number of subjects: 260
Study 25948426 — intervention group
Group type: EXPERIMENTAL
Intervention: Shiatsu technique (30 seconds on three points by an experienced midwife)
Number of subjects: 288
Study 25948426 — intervention group
Group type: COMPARATOR
Intervention: Routine procedure (control group)
Number of subjects: 288
Study 21778014 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (PRP)
Number of subjects: 15
Study 21778014 — intervention group
Group type: COMPARATOR
Intervention: Blood clot (control group)
Number of subjects: 15
Study 20710020 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg kg(‐1) bolus dose followed by a 5‐20‐40‐120 min, 10‐8‐6‐5 mg kg(‐1) h(‐1) infusion.
Number of subjects: 19
Study 20710020 — intervention group
Group type: EXPERIMENTAL
Intervention: Allometric model using total body weight (TBW) as the size descriptor.
Number of subjects: 19
Study 20710020 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled analysis from 51 patients including obese and non-obese data.
Number of subjects: 19
Study 18096680 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral Ischaemia and Atrial Fibrillation (CIAF)
Number of subjects: 2659
Study 18096680 — intervention group
Group type: COMPARATOR
Intervention: Cerebral Ischaemia of Arterial Origin (CIAO)
Number of subjects: 2659
Study 16171718 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (n = 7)
Number of subjects: 24
Study 16171718 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progesterone (n = 8)
Number of subjects: 24
Study 16171718 — intervention group
Group type: COMPARATOR
Intervention: No hormone replacement (n = 9)
Number of subjects: 24
Study 12767571 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 150 mg administered orally on days 5 through 9 of the CC-induced cycle
Number of subjects: 20
Study 12767571 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous cycles
Number of subjects: 20
Study 10489026 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a 22 microg weekly
Number of subjects: 0
Study 10489026 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a 44 microg weekly
Number of subjects: 0
Study 10489026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10180841 — intervention group
Group type: EXPERIMENTAL
Intervention: 38-item module on BPH-specific health status first, followed by a 30-item module on overall health status
Number of subjects: 392
Study 10180841 — intervention group
Group type: COMPARATOR
Intervention: 30-item module on overall health status first, followed by a 38-item module on BPH-specific health status
Number of subjects: 392
Study 1881695 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 30
Study 1881695 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin + Metronidazole
Number of subjects: 30
Study 6378355 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic granulocyte transfusions (PGT)
Number of subjects: 35
Study 6378355 — intervention group
Group type: COMPARATOR
Intervention: Control (no prophylactic granulocyte transfusions)
Number of subjects: 35
Study 31488462 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare Transformation Plan (HTP) implemented in Iran in 2016
Number of subjects: 200
Study 31488462 — intervention group
Group type: COMPARATOR
Intervention: Pre-reform group (2012)
Number of subjects: 200
Study 31488462 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-reform group (2016)
Number of subjects: 200
Study 31488462 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-HTP (2016)
Number of subjects: 200
Study 31488462 — intervention group
Group type: COMPARATOR
Intervention: Pre-HTP (2012)
Number of subjects: 200
Study 29959105 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention for increasing physical activity (n = 140)
Number of subjects: 280
Study 29959105 — intervention group
Group type: COMPARATOR
Intervention: Attention and social contact control (n = 140)
Number of subjects: 280
Study 26999243 — intervention group
Group type: EXPERIMENTAL
Intervention: sLPD (0.6 g/kg/d with 0.09 g/kg/d keto acids)
Number of subjects: 108
Study 26999243 — intervention group
Group type: COMPARATOR
Intervention: NPD (1.0 g/kg/d)
Number of subjects: 108
Study 24534120 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided fiducial seed placement alone
Number of subjects: 285
Study 24534120 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided fiducial seed placement with concurrent biopsy
Number of subjects: 285
Study 24534120 — intervention group
Group type: COMPARATOR
Intervention: Core biopsy alone
Number of subjects: 285
Study 24534120 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (fiducial only, biopsy only, combined)
Number of subjects: 285
Study 24534120 — intervention group
Group type: COMPARATOR
Intervention: Fiducial only
Number of subjects: 285
Study 24534120 — intervention group
Group type: COMPARATOR
Intervention: Biopsy only
Number of subjects: 285
Study 22186223 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with potassium bromide (1 g, tid) and methimazole (10 mg, tid)
Number of subjects: 60
Study 22186223 — intervention group
Group type: COMPARATOR
Intervention: Methimazole only (10 mg, tid) with starch placebo (1 g, tid)
Number of subjects: 60
Study 20397591 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspicion as a source feature
Number of subjects: 0
Study 20397591 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspicion as a receptor's personal disposition
Number of subjects: 0
Study 20397591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispositional suspicion
Number of subjects: 0
Study 22766026 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG)
Number of subjects: 57
Study 22766026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 15695749 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs)
Number of subjects: 164
Study 15695749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 15695749 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls and epilepsy patient controls
Number of subjects: 164
Study 12721780 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.25, 0.50, 0.75 g/kg based on total body water)
Number of subjects: 32
Study 12721780 — intervention group
Group type: COMPARATOR
Intervention: No alcohol administration
Number of subjects: 32
Study 10226770 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) administered orally to 24 patients
Number of subjects: 45
Study 10226770 — intervention group
Group type: COMPARATOR
Intervention: Control group of 21 patients without pentoxifylline administration
Number of subjects: 45
Study 8679274 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplementation with beta-carotene (30 mg/d) and alpha-tocopherol (400 IU/d)
Number of subjects: 0
Study 8679274 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study 1859950 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal alcohol consumption before and after pregnancy
Number of subjects: 846
Study 1859950 — intervention group
Group type: COMPARATOR
Intervention: No alcohol consumption
Number of subjects: 846
Study 6413133 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched chain amino acid (BcAA) enriched parenteral nutrition at doses of 0.16, 0.3, 0.5, and 0.7 g/kg . day
Number of subjects: 32
Study 6413133 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched chain amino acid (BcAA) enriched parenteral nutrition
Number of subjects: 32
Study 6413133 — intervention group
Group type: COMPARATOR
Intervention: Balanced nutritional support with 30 glucose cal/kg . day and 7 cal/kg . day of iv fat
Number of subjects: 32
Study 29248827 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling
Number of subjects: 200
Study 29248827 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary counseling)
Number of subjects: 200
Study 23907163 — intervention group
Group type: EXPERIMENTAL
Intervention: Curriculum progression adjustments based on formative assessments (e.g. repeat lessons, skip lessons) every 4 weeks.
Number of subjects: 136
Study 23907163 — intervention group
Group type: COMPARATOR
Intervention: Standard implementation without adjustments (control group, n = 101).
Number of subjects: 136
Study 23110783 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure to artichoke (10 exposures)
Number of subjects: 72
Study 23110783 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavour-flavour learning (10 exposures to artichoke)
Number of subjects: 72
Study 23110783 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavour-nutrient learning (10 exposures to artichoke)
Number of subjects: 72
Study 23110783 — intervention group
Group type: COMPARATOR
Intervention: Control vegetable (carrot)
Number of subjects: 72
Study 20600032 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (3 mg, three times daily or twice daily) + Azathioprine (1-2 mg/kg/d)
Number of subjects: 203
Study 20600032 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (40 mg/d, tapered to 10 mg/d) + Azathioprine (1-2 mg/kg/d)
Number of subjects: 203
Study 20600032 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (after 6 months of prednisone) + Azathioprine (1-2 mg/kg/d)
Number of subjects: 203
Study 18251597 — intervention group
Group type: EXPERIMENTAL
Intervention: Eruption guidance appliance
Number of subjects: 115
Study 18251597 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study 17109751 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid-pump procedure
Number of subjects: 109
Study 17109751 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary bypass
Number of subjects: 109
Study 12626350 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral arginine therapy
Number of subjects: 10
Study 12626350 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginase activity measurement
Number of subjects: 10
Study 10741622 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral nisoldipine with 200 mL grapefruit juice (G0)
Number of subjects: 8
Study 10741622 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral nisoldipine with 200 mL grapefruit juice (G14)
Number of subjects: 8
Study 10741622 — intervention group
Group type: COMPARATOR
Intervention: 10 mg oral nisoldipine with water (control)
Number of subjects: 8
Study 10741622 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral nisoldipine with water (G38)
Number of subjects: 8
Study 10741622 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral nisoldipine with water (G72)
Number of subjects: 8
Study 10741622 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral nisoldipine with water (G96)
Number of subjects: 8
Study 10741622 — intervention group
Group type: EXPERIMENTAL
Intervention: G0, G14, G38
Number of subjects: 8
Study 10741622 — intervention group
Group type: EXPERIMENTAL
Intervention: G0
Number of subjects: 8
Study 9015467 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofibrate 100 mg once daily
Number of subjects: 174
Study 9015467 — intervention group
Group type: COMPARATOR
Intervention: Bezafibrate 400 mg once daily
Number of subjects: 174
Study 1999932 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle-sparing thoracotomy
Number of subjects: 50
Study 1999932 — intervention group
Group type: COMPARATOR
Intervention: Standard posterolateral thoracotomy
Number of subjects: 50
Study 6352622 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftazidime 2 g bd
Number of subjects: 50
Study 6352622 — intervention group
Group type: COMPARATOR
Intervention: cefamandole 2 g tds and tobramycin 80 mg bd
Number of subjects: 50
Study 30549498 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 60
Study 30549498 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 60
Study 26164019 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.025 μg) once daily for 14 days
Number of subjects: 28
Study 26164019 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule once daily for 14 days
Number of subjects: 28
Study 26164019 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline vitamin D level association
Number of subjects: 28
Study 24931840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-match-compatible platelets
Number of subjects: 40
Study 24931840 — intervention group
Group type: COMPARATOR
Intervention: Randomly selected and incompatible platelets
Number of subjects: 40
Study 22735900 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 54
Study 20851460 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% PRO2000 gel
Number of subjects: 9385
Study 20851460 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% PRO2000 gel
Number of subjects: 9385
Study 20851460 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 9385
Study 18270569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 455
Study 18270569 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine + Sulfadoxine-pyrimethamine (AQ+SP)
Number of subjects: 455
Study 18270569 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine + Sulfadoxine-pyrimethamine (CQ+SP)
Number of subjects: 455
Study 18270569 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate + Sulfadoxine-pyrimethamine (ART+SP)
Number of subjects: 455
Study 15708255 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF) radiotherapy, 2 Gy daily up to 60 Gy in 6 weeks
Number of subjects: 226
Study 15708255 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF) radiotherapy, biphasic concomitant boost schedule delivering 64 Gy in 5 weeks
Number of subjects: 226
Study 15708255 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF) radiotherapy
Number of subjects: 226
Study 15708255 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF) radiotherapy
Number of subjects: 226
Study 11870157 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose radiation therapy (64.8 Gy)
Number of subjects: 236
Study 11870157 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose radiation therapy (50.4 Gy)
Number of subjects: 236
Study 10203111 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual preventive in-home comprehensive geriatric assessment (CGA) with quarterly home visits by gerontologic nurse practitioners for 3 years
Number of subjects: 294
Study 7572737 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt preload (low-fat, low-energy, 962 kJ)
Number of subjects: 32
Study 7572737 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt preload (high-fat, high-energy, 2134 kJ)
Number of subjects: 32
Study 7572737 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt preload (high-carbohydrate, high-energy, 2134 kJ)
Number of subjects: 32
Study 7572737 — intervention group
Group type: COMPARATOR
Intervention: No yogurt (baseline condition)
Number of subjects: 32
Study 2331093 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighted stylet
Number of subjects: 80
Study 2331093 — intervention group
Group type: COMPARATOR
Intervention: Blind nasotracheal intubation
Number of subjects: 80
Study 299220 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐antigen immunotherapy combined with cytostatic therapy
Number of subjects: 40
Study 299220 — intervention group
Group type: COMPARATOR
Intervention: Cytostatics only
Number of subjects: 40
Study 31468656 — intervention group
Group type: EXPERIMENTAL
Intervention: Xbox KinectTM games training
Number of subjects: 16
Study 31468656 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy older adults)
Number of subjects: 16
Study 31468656 — intervention group
Group type: COMPARATOR
Intervention: Control group (PD patients)
Number of subjects: 16
Study 30607757 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-adapted Cognitive Processing Therapy (CPT)
Number of subjects: 73
Study 30607757 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (Control)
Number of subjects: 73
Study 27902945 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial cervical disc replacement (ACDR) with Prestige-LP prosthesis
Number of subjects: 25
Study 26432120 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifocal IOLs (Finevision Micro F)
Number of subjects: 28
Study 26432120 — intervention group
Group type: COMPARATOR
Intervention: Bifocal IOLs (Acrysof IQ Restor +3.0)
Number of subjects: 28
Study 26432120 — intervention group
Group type: COMPARATOR
Intervention: Comparison of trifocal vs bifocal IOLs
Number of subjects: 28
Study 23435303 — intervention group
Group type: EXPERIMENTAL
Intervention: Philani Intervention Program (PIP) - home visits by community health workers (CHWs) in addition to standard care
Number of subjects: 644
Study 23435303 — intervention group
Group type: COMPARATOR
Intervention: Standard care - comprehensive healthcare at clinics
Number of subjects: 644
Study 21421179 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30 mg/d
Number of subjects: 314
Study 21421179 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 mg/d
Number of subjects: 314
Study 21421179 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 70 mg/d
Number of subjects: 314
Study 21421179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 21421179 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) (all doses combined)
Number of subjects: 314
Study 19183976 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented group (stent placed)
Number of subjects: 228
Study 19183976 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stent placed)
Number of subjects: 228
Study 19183976 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (no stent, no marked ureteral edema)
Number of subjects: 228
Study 19183976 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (stent placed, with marked ureteral edema)
Number of subjects: 228
Study 19183976 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (stent placed, with polypoid change)
Number of subjects: 228
Study 18235907 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% phenylephrine
Number of subjects: 28
Study 18235907 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.0% phenylephrine
Number of subjects: 28
Study 18235907 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 10.0% phenylephrine vs 2.5% phenylephrine
Number of subjects: 28